Aud Dorothea Svindland

• Ouellet, Véronique; Erickson, Andrew; Wiley, Kathy; Morrissey, Colm; Berge, Viktor & Moreno, Carlos S. [Show all 31 contributors for this article] (2022). The movember global action plan 1 (GAP1): Unique prostate cancer tissue microarray resource. Cancer Epidemiology, Biomarkers and Prevention. ISSN 1055-9965. 31(4), p. 715–727. doi: 10.1158/1055-9965.EPI-21-0600. Full text in Research Archive Show summary

  Abstract Background: The need to better understand the molecular underpinnings of the heterogeneous outcomes of patients with prostate cancer is a pressing global problem and a key research priority for Movember. To address this, the Movember Global Action Plan 1 Unique tissue microarray (GAP1-UTMA) project constructed a set of unique and richly annotated tissue microarrays (TMA) from prostate cancer samples obtained from multiple institutions across several global locations. Methods: Three separate TMA sets were built that differ by purpose and disease state. Results: The intended use of TMA1 (Primary Matched LN) is to validate biomarkers that help determine which clinically localized prostate cancers with associated lymph node metastasis have a high risk of progression to lethal castration-resistant metastatic disease, and to compare molecular properties of high-risk index lesions within the prostate to regional lymph node metastases resected at the time of prostatectomy. TMA2 (Pre vs. Post ADT) was designed to address questions regarding risk of castration-resistant prostate cancer (CRPC) and response to suppression of the androgen receptor/androgen axis, and characterization of the castration-resistant phenotype. TMA3 (CRPC Met Heterogeneity)'s intended use is to assess the heterogeneity of molecular markers across different anatomic sites in lethal prostate cancer metastases. Conclusions: The GAP1-UTMA project has succeeded in combining a large set of tissue specimens from 501 patients with prostate cancer with rich clinical annotation. Impact: This resource is now available to the prostate cancer community as a tool for biomarker validation to address important unanswered clinical questions around disease progression and response to treatment.

• Bergsland, Christian Holst; Jeanmougin, Marine; Moosavi, Seyed Hossein; Svindland, Aud; Bruun, Jarle & Nesbakken, Arild [Show all 8 contributors for this article] (2022). Spatial analysis and CD25-expression identify regulatory T cells as predictors of a poor prognosis in colorectal cancer. Modern Pathology. ISSN 0893-3952. 35, p. 1236–1246. doi: 10.1038/s41379-022-01086-8. Full text in Research Archive Show summary

  Regulatory T cells (Tregs) are a heterogeneous cell population that can either suppress or stimulate immune responses. Tumor-infiltrating Tregs are associated with an adverse outcome from most cancer types, but have generally been found to be associated with a good prognosis in colorectal cancer (CRC). We investigated the prognostic heterogeneity of Tregs in CRC by co-expression patterns and spatial analyses with diverse T cell markers, using multiplex fluorescence immunohistochemistry and digital image analysis in two consecutive series of primary CRCs (total n = 1720). Treg infiltration in tumors, scored as FOXP3+ or CD4+/CD25+/FOXP3+ (triple-positive) cells, was strongly correlated to the overall amount of CD3+ and CD8+ T cells, and consequently associated with a favorable 5-year relapse-free survival rate among patients with stage I–III CRC who underwent complete tumor resection. However, high relative expression of the activation marker CD25 in triple-positive Tregs was independently associated with an adverse outcome in a multivariable model incorporating clinicopathological and known molecular prognostic markers (hazard ratio = 1.35, p = 0.028). Furthermore, spatial marker analysis based on Voronoi diagrams and permutation testing of cellular neighborhoods revealed a statistically significant proximity between Tregs and CD8+-cells in 18% of patients, and this was independently associated with a poor survival (multivariable hazard ratio = 1.36, p = 0.017). These results show prognostic heterogeneity of different Treg populations in primary CRC, and highlight the importance of multi-marker and spatial analyses for accurate immunophenotyping of tumors in relation to patient outcome.

• Hopland, Ola Andreas; Fosså, Sophie Dorothea; Ottosson, Fredrik; Brennhovd, Bjørn; Svindland, Aud & Hole, Knut Håkon [Show all 10 contributors for this article] (2021). Robotic salvage pelvic lymph node dissection for locoregional recurrence after radical prostatectomy: a single institution experience. Scandinavian Journal of Urology. ISSN 2168-1805. 55(4). doi: 10.1080/21681805.2021.1946135. Full text in Research Archive Show summary

  Objectives To assess treatment response (PSA < 0.2 ng/ml), need for additional therapy and complication rate after robot assisted salvage pelvic lymph node dissection (sPLND) Material and Methods Analysis of outcomes data from radical prostatectomy (RP) patients consecutively operated with robot assisted sPLND due to biochemical recurrence and positron-emission tomography (PET)/computed tomography (CT)-detected nodal recurrence of pelvic lymph nodes. Results Sixty-nine patients underwent robotic sPLND after a median time of 47 months post- RP. Sixty-four patients (93%) had malignant lymph nodes upon histological assessment of sPLND specimen. Twenty patients (29%) achieved PSA < 0.2 ng/ml 6 weeks postoperatively. After median (IQR) follow-up of 15 months (10–27), fourteen patients (20%) still had PSA < 0.2 ng/ml without additional therapy and forty-one patients (59%) had started additional therapy. No significant predictor for treatment response was found. Postoperative complications occurred in 14 patients (20%). Eleven of these complications were classified as Clavien-Dindo grade 1 Conclusion Oncological benefit of sPLND as the only salvage procedure seems to be limited, though almost one third of patients achieved treatment response. Clinical trials are needed to determine if sPLND as part of a multimodal treatment may improve outcome.

• Bruun, Jarle; Eide, Peter Andreas Wold; Bergsland, Christian Holst; Brück, Oscar; Svindland, Aud & Arjama, Mariliina [Show all 13 contributors for this article] (2021). E-cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models. Molecular Oncology. ISSN 1574-7891. 00, p. 1–18. doi: 10.1002/1878-0261.13159. Full text in Research Archive Show summary

  Cell–cell and cell–matrix adhesion proteins that have been implicated in colorectal epithelial integrity and epithelial-to-mesenchymal transition could be robust prognostic and potential predictive biomarkers for standard and novel therapies. We analyzed in situ protein expression of E-cadherin (ECAD), integrin β4 (ITGB4), zonula occludens 1 (ZO-1), and cytokeratins in a single-hospital series of Norwegian patients with colorectal cancer (CRC) stages I–IV (n = 922) using multiplex fluorescence-based immunohistochemistry (mfIHC) on tissue microarrays. Pharmacoproteomic associations were explored in 35 CRC cell lines annotated with drug sensitivity data on > 400 approved and investigational drugs. ECAD, ITGB4, and ZO-1 were positively associated with survival, while cytokeratins were negatively associated with survival. Only ECAD showed independent prognostic value in multivariable Cox models. Clinical and molecular associations for ECAD were technically validated on a different mfIHC platform, and the prognostic value was validated in another Norwegian series (n = 798). In preclinical models, low and high ECAD expression differentially associated with sensitivity to topoisomerase, aurora, and HSP90 inhibitors, and EGFR inhibitors. E-cadherin protein expression is a robust prognostic biomarker with potential clinical utility in CRC.

• Ramberg, Håkon Andre; Richardsen, Elin; Souza, Gustavo Antonio De; Rakaee, Mehrdad; Stensland, Maria & Braadland, Peder Rustøen [Show all 13 contributors for this article] (2021). Proteomic analyses identify major vault protein as a prognostic biomarker for fatal prostate cancer. Carcinogenesis. ISSN 0143-3334. 42(5), p. 685–693. doi: 10.1093/carcin/bgab015. Full text in Research Archive Show summary

  The demographic shift toward an older population will increase the number of prostate cancer cases. A challenge in the treatment of prostate cancer is to avoid undertreatment of patients at high risk of progression following curative treatment. These men can benefit from early salvage treatment. An explorative cohort consisting of tissue from 16 patients who underwent radical prostatectomy, and were either alive or had died from prostate cancer within 10 years postsurgery, was analyzed by mass spectrometry analysis. Following proteomic and bioinformatic analyses, major vault protein (MVP) was identified as a putative prognostic biomarker. A publicly available tissue proteomics dataset and a retrospective cohort of 368 prostate cancer patients were used for validation. The prognostic value of the MVP was verified by scoring immunohistochemical staining of a tissue microarray. High level of MVP was associated with more than 4-fold higher risk for death from prostate cancer (hazard ratio = 4.41, 95% confidence interval: 1.45–13.38; P = 0.009) in a Cox proportional hazard models, adjusted for Cancer of the Prostate Risk Assessments Post-surgical (CAPRA-S) score and perineural invasion. Decision curve analyses suggested an improved standardized net benefit, ranging from 0.06 to 0.18, of adding MVP onto CAPRA-S score. This observation was confirmed by receiver operator characteristics curve analyses for the CAPRA-S score versus CAPRA-S and MVP score (area under the curve: 0.58 versus 0.73). From these analyses, one can infer that MVP levels in combination with CAPRA-S score might add onto established risk parameters to identify patients with lethal prostate cancer.

• Bergsland, Christian Holst; Bruun, Jarle; Guren, Marianne; Svindland, Aud; Bjørnslett, Merete Pauline & Smeby, Jørgen [Show all 16 contributors for this article] (2020). Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancer. ESMO Open. 5:e001040(6), p. 1–12. doi: 10.1136/esmoopen-2020-001040. Full text in Research Archive Show summary

  Background There is a need for improved selection of patients for adjuvant chemotherapy after resection of non-metastatic colorectal cancer (CRC). Regulator of chromosome condensation 2 (RCC2) is a potential prognostic biomarker. We report on the establishment of a robust protocol for RCC2 expression analysis and prognostic tumour biomarker evaluation in patients who did and did not receive adjuvant chemotherapy. Materials and methods RCC2 was analysed in 2916 primary CRCs from the QUASAR2 randomised trial and two single-hospital Norwegian series. A new protocol using fluorescent antibody staining and digital image analysis was optimised. Biomarker value for 5-year relapse-free survival was analysed in relation to tumour stage, adjuvant chemotherapy and the molecular markers microsatellite instability, KRAS/BRAFV600E/TP53 mutations and CDX2 expression. Results Low RCC2 expression was scored in 41% of 2696 evaluable samples. Among patients with stage I–III CRC who had not received adjuvant chemotherapy, low RCC2 expression was an independent marker of inferior 5-year relapse-free survival in multivariable Cox models including clinicopathological factors and molecular markers (HR 1.45, 95% CI 1.09 to 1.94, p=0.012, N=521). RCC2 was not prognostic in patients who had received adjuvant chemotherapy, neither in QUASAR2 nor the pooled Norwegian series. The interaction between RCC2 and adjuvant chemotherapy for prediction of patient outcome was significant in stage III, and strongest among patients with microsatellite stable tumours (pinteraction=0.028). Conclusions Low expression of RCC2 is a biomarker for poor prognosis in patients with stage I–III CRC and seems to be a predictive biomarker for effect of adjuvant chemotherapy.

• Lund, Tormod; Svindland, Aud; Bay, Dag; Sundhagen, Jon Otto; Hisdal, Jonny & Flørnes, Tor Leif (2020). Histological Analysis of a Long Term Patent Subintimal Canal in theSuperficial Femoral Artery. EJVES Short Reports. 50, p. 19–23. doi: 10.1016/j.ejvsvf.2020.12.023. Full text in Research Archive Show summary

  The subintimal canal was created in the medial layer of the vessel wall. Early and late stage atherosclerosis is observed throughout the subintimal canal. Neo-cellularisation of single layer luminal cells is apparent in the subintimal canal. The findings underscore the need for surveillance of subintimal canals.

• Lopes, Nair Susana da Costa Florim Ribeiro; Bergsland, Christian Holst; Bjørnslett, Merete Pauline; Pellinen, Teijo Severi; Svindland, Aud & Nesbakken, Arild [Show all 10 contributors for this article] (2019). Digital image analysis of multiplex fluorescence IHC in colorectal cancer recognizes the prognostic value of CDX2 and its negative correlation with SOX2. Laboratory Investigation. ISSN 0023-6837. 100(1), p. 120–134. doi: 10.1038/s41374-019-0336-4. Full text in Research Archive Show summary

  Flourescence-based multiplex immunohistochemistry (mIHC) combined with multispectral imaging and digital image analysis (DIA) is a quantitative high-resolution method for determination of protein expression in tissue. We applied this method for five biomarkers (CDX2, SOX2, SOX9, E-cadherin, and β-catenin) using tissue microarrays of a Norwegian unselected series of primary colorectal cancer. The data were compared with previously obtained chromogenic IHC data of the same tissue cores, visually assessed by the Allred method. We found comparable results between the methods, although confirmed that DIA offered improved resolution to differentiate cases with high and low protein expression. However, we experienced inherent challenges with digital image analysis of membrane staining, which was better assessed visually. DIA and mIHC enabled quantitative analysis of biomarker coexpression on the same tissue section at the single-cell level, revealing a strong negative correlation between the differentiation markers CDX2 and SOX2. Both methods confirmed known prognostic associations for CDX2, but DIA improved data visualization and detection of clinicopathological and biological associations. In summary, mIHC combined with DIA is an efficient and reliable method to evaluate protein expression in tissue, here shown to recapitulate and improve detection of known clinicopathological and survival associations for the emerging biomarker CDX2, and is therefore a candidate approach to standardize CDX2 detection in pathology laboratories.

• Braadland, Peder Rustøen; Ramberg, Håkon Andre; Grytli, Helene Hartvedt; Urbanucci, Alfonso; Nielsen, Heidi Kristin & Guldvik, Ingrid Jenny [Show all 13 contributors for this article] (2019). The β2-adrenergic receptor is a molecular switch for neuroendocrine transdifferentiation of prostate cancer cells. Molecular Cancer Research. ISSN 1541-7786. 17(11), p. 2154–2168. doi: 10.1158/1541-7786.MCR-18-0605. Full text in Research Archive
• Danielsen, Håvard Emil; Hveem, Tarjei Sveinsgjerd; Domingo, Enric; Pradhan, Manohar; Kleppe, Andreas & Syvertsen, Rolf Anders [Show all 18 contributors for this article] (2018). Prognostic markers for colorectal cancer: Estimating ploidy and stroma. Annals of Oncology. ISSN 0923-7534. 29(3), p. 616–623. doi: 10.1093/annonc/mdx794. Full text in Research Archive
• Bruun, Jarle; Sveen, Anita; Barros, Rita; Eide, Peter Andreas Wold; Eilertsen, Ina Andrassy & Kolberg, Matthias [Show all 14 contributors for this article] (2018). Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer. Molecular Oncology. ISSN 1574-7891. 12(9), p. 1639–1655. doi: 10.1002/1878-0261.12347. Full text in Research Archive Show summary

  We aimed to refine the value of CDX2 as an independent prognostic and predictive biomarker in colorectal cancer (CRC) according to disease stage and chemotherapy sensitivity in preclinical models. CDX2 expression was evaluated in 1045 stage I–IV primary CRCs by gene expression (n = 403) or immunohistochemistry (n = 642) and in relation to 5‐year relapse‐free survival (RFS), overall survival (OS), and chemotherapy. Pharmacogenomic associations between CDX2 expression and 69 chemotherapeutics were assessed by drug screening of 35 CRC cell lines. CDX2 expression was lost in 11.6% of cases and showed independent poor prognostic value in multivariable models. For individual stages, CDX2 was prognostic only in stage IV, independent of chemotherapy. Among stage I–III patients not treated in an adjuvant setting, CDX2 loss was associated with a particularly poor survival in the BRAF‐mutated subgroup, but prognostic value was independent of microsatellite instability status and the consensus molecular subtypes. In stage III, the 5‐year RFS rate was higher among patients with loss of CDX2 who received adjuvant chemotherapy than among patients who did not. The CDX2‐negative cell lines were significantly more sensitive to chemotherapeutics than CDX2‐positive cells, and the multidrug resistance genes MDR1 and CFTR were significantly downregulated both in CDX2‐negative cells and in patient tumors. Loss of CDX2 in CRC is an adverse prognostic biomarker only in stage IV disease and appears to be associated with benefit from adjuvant chemotherapy in stage III. Early‐stage patients not qualifying for chemotherapy might be reconsidered for such treatment if their tumor has loss of CDX2 and mutated BRAF.

• Prencipe, Maria; Fabre, Aurelie; Murphy, Thomas Brendan; Vargyas, Eszter; O'Neill, Amanda & Bjartell, Anders [Show all 13 contributors for this article] (2018). Role of serum response factor expression in prostate cancer biochemical recurrence. The Prostate. ISSN 0270-4137. 78(10), p. 724–730. doi: 10.1002/pros.23516. Full text in Research Archive
• Bilir, Birdal; Sharma, Nitya V.; Lee, Jeongseok; Hammarström, Bato; Svindland, Aud & Kucuk, Omer [Show all 7 contributors for this article] (2017). Effects of genistein supplementation on genome-wide DNA methylation and gene expression in patients with localized prostate cancer. International Journal of Oncology. ISSN 1019-6439. 51(1), p. 223–234. doi: 10.3892/ijo.2017.4017. Full text in Research Archive
• Braadland, Peder; Giskeødegård, Guro F.; Sandsmark, Elise; Bertilsson, Helena; Euceda, Leslie R. & Hansen, Ailin Falkmo [Show all 17 contributors for this article] (2017). Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy. British Journal of Cancer. ISSN 0007-0920. 117(11), p. 1656–1664. doi: 10.1038/bjc.2017.346. Full text in Research Archive Show summary

  Background: Robust biomarkers that identify prostate cancer patients with high risk of recurrence will improve personalised cancer care. In this study, we investigated whether tissue metabolites detectable by high-resolution magic angle spinning magnetic resonance spectroscopy (HR-MAS MRS) were associated with recurrence following radical prostatectomy. Methods: We performed a retrospective ex vivo study using HR-MAS MRS on tissue samples from 110 radical prostatectomy specimens obtained from three different Norwegian cohorts collected between 2002 and 2010. At the time of analysis, 50 patients had experienced prostate cancer recurrence. Associations between metabolites, clinicopathological variables, and recurrence-free survival were evaluated using Cox proportional hazards regression modelling, Kaplan–Meier survival analyses and concordance index (C-index). Results: High intratumoural spermine and citrate concentrations were associated with longer recurrence-free survival, whereas high (total-choline+creatine)/spermine (tChoCre/Spm) and higher (total-choline+creatine)/citrate (tChoCre/Cit) ratios were associated with shorter time to recurrence. Spermine concentration and tChoCre/Spm were independently associated with recurrence in multivariate Cox proportional hazards modelling after adjusting for clinically relevant risk factors (C-index: 0.769; HR: 0.72; P=0.016 and C-index: 0.765; HR: 1.43; P=0.014, respectively). Conclusions: Spermine concentration and tChoCre/Spm ratio in prostatectomy specimens were independent prognostic markers of recurrence. These metabolites can be noninvasively measured in vivo and may thus offer predictive value to establish preoperative risk assessment nomograms.

• Walker, Steven M.; Knight, Laura A.; McCavigan, Andrena M.; Logan, Gemma E.; Berge, Viktor & Sherif, Amir [Show all 27 contributors for this article] (2017). Molecular subgroup of primary prostate cancer presenting with metastatic biology. European Urology. ISSN 0302-2838. 72(4), p. 509–518. doi: 10.1016/j.eururo.2017.03.027. Full text in Research Archive Show summary

  Background Approximately 4–25% of patients with early prostate cancer develop disease recurrence following radical prostatectomy. Objective To identify a molecular subgroup of prostate cancers with metastatic potential at presentation resulting in a high risk of recurrence following radical prostatectomy. Design, setting, and participants Unsupervised hierarchical clustering was performed using gene expression data from 70 primary resections, 31 metastatic lymph nodes, and 25 normal prostate samples. Independent assay validation was performed using 322 radical prostatectomy samples from four sites with a mean follow-up of 50.3 months. Outcome measurements and statistical analysis Molecular subgroups were identified using unsupervised hierarchical clustering. A partial least squares approach was used to generate a gene expression assay. Relationships with outcome (time to biochemical and metastatic recurrence) were analysed using multivariable Cox regression and log-rank analysis. Results and limitations A molecular subgroup of primary prostate cancer with biology similar to metastatic disease was identified. A 70-transcript signature (metastatic assay) was developed and independently validated in the radical prostatectomy samples. Metastatic assay positive patients had increased risk of biochemical recurrence (multivariable hazard ratio [HR] 1.62 [1.13–2.33]; p = 0.0092) and metastatic recurrence (multivariable HR = 3.20 [1.76–5.80]; p = 0.0001). A combined model with Cancer of the Prostate Risk Assessment post surgical (CAPRA-S) identified patients at an increased risk of biochemical and metastatic recurrence superior to either model alone (HR = 2.67 [1.90–3.75]; p < 0.0001 and HR = 7.53 [4.13–13.73]; p < 0.0001, respectively). The retrospective nature of the study is acknowledged as a potential limitation. Conclusions The metastatic assay may identify a molecular subgroup of primary prostate cancers with metastatic potential. Patient summary The metastatic assay may improve the ability to detect patients at risk of metastatic recurrence following radical prostatectomy. The impact of adjuvant therapies should be assessed in this higher-risk population.

• Vedeld, Hege Marie; Merok, Marianne Aarstad; Jeanmougin, Marine; Danielsen, Stine Aske; Honne, Hilde & Presthus, Gro [Show all 13 contributors for this article] (2017). CpG island methylator phenotype identifies high risk patients among microsatellite stable BRAF mutated colorectal cancers. International Journal of Cancer. ISSN 0020-7136. 141(5), p. 967–976. doi: 10.1002/ijc.30796. Full text in Research Archive
• Vatne, Kari; Stensvold, Andreas; Myklebust, Tor Åge; Møller, Bjørn; Svindland, Aud & Kvåle, Rune [Show all 7 contributors for this article] (2017). Pre- and post-prostatectomy variables associated with pelvic post-operative radiotherapy in prostate cancer patients: a national registry-based study. Acta Oncologica. ISSN 0284-186X. 56(10), p. 1295–1301. doi: 10.1080/0284186X.2017.1314006. Full text in Research Archive
• Paur, Ingvild; Lilleby, Wolfgang; Bøhn, Siv Kjølsrud; Hulander, Erik; Klein, Willibrord & Vlatkovic, Ljiljana [Show all 19 contributors for this article] (2016). Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA. Clinical Nutrition. ISSN 0261-5614. 36(3), p. 672–679. doi: 10.1016/j.clnu.2016.06.014. Full text in Research Archive Show summary

  Background & aims: The effect of lycopene-containing foods in prostate cancer development remains undetermined. We tested whether a lycopene-rich tomato intervention could reduce the levels of prostate specific antigen (PSA) in prostate cancer patients. Methods: Prior to their curative treatment, 79 patients with prostate cancer were randomized to a nutritional intervention with either 1) tomato products containing 30 mg lycopene per day; 2) tomato products plus selenium, omega-3 fatty acids, soy isoflavones, grape/pomegranate juice, and green/black tea (tomato-plus); or 3) control diet for 3 weeks. Results: The main analysis, which included patients in all risk categories, did not reveal differences in changes of PSA-values between the intervention and control groups. Post-hoc, exploratory analyses within intermediate risk (n = 41) patients based on tumor classification and Gleason score post-surgery, revealed that median PSA decreased significantly in the tomato group as compared to controls (−2.9% and +6.5% respectively, p = 0.016). In separate post-hoc analyses, we observed that median PSA-values decreased by 1% in patients with the highest increases in plasma lycopene, selenium and C20:5 n-3 fatty acid, compared to an 8.5% increase in the patients with the lowest increase in lycopene, selenium and C20:5 n-3 fatty acid (p = 0.003). Also, PSA decreased in patients with the highest increase in lycopene alone (p = 0.009). Conclusions: Three week nutritional interventions with tomato-products alone or in combination with selenium and n-3 fatty acids lower PSA in patients with non-metastatic prostate cancer. Our observation suggests that the effect may depend on both aggressiveness of the disease and the blood levels of lycopene, selenium and omega-3 fatty acids.

• Baco, Eduard; Rud, Erik; Eri, Lars Magne; Moen, Gunnar; Vlatkovic, Ljiljana & Svindland, Aud [Show all 8 contributors for this article] (2016). A Randomized Controlled Trial to Assess and Compare the Outcomes of Two-core Prostate Biopsy Guided by Fused Magnetic Resonance and Transrectal Ultrasound Images and Traditional 12-core Systematic Biopsy. European Urology. ISSN 0302-2838. 69(1), p. 149–156. doi: 10.1016/j.eururo.2015.03.041. Full text in Research Archive
• Ramberg, Håkon Andre; Grytli, Helene Hartvedt; Nygård, Ståle; Wang, Wanzhong; Øgren, Hans Olav & Zhao, Sen [Show all 14 contributors for this article] (2016). PBX3 is a putative biomarker of aggressive prostate cancer. International Journal of Cancer. ISSN 0020-7136. 139(8), p. 1810–1820. doi: 10.1002/ijc.30220. Full text in Research Archive
• Braadland, Peder; Grytli, Helene Hartvedt; Ramberg, Håkon Andre; Katz, Betina; Kellmann, Ralf & Gauthier-Landry, louis [Show all 18 contributors for this article] (2016). Low β2-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism. OncoTarget. 7(2), p. 1878–1894. doi: 10.18632/oncotarget.6479. Full text in Research Archive Show summary

  The underlying mechanisms responsible for the development of castration-resistant prostate cancer (CRPC) in patients who have undergone androgen deprivation therapy are not fully understood. This is the first study to address whether β2-adrenergic receptor (ADRB2)- mediated signaling may affect CRPC progression in vivo. By immunohistochemical analyses, we observed that low levels of ADRB2 is associated with a more rapid development of CRPC in a Norwegian patient cohort. To elucidate mechanisms by which ADRB2 may affect CRPC development, we stably transfected LNCaP cells with shRNAs to mimic low and high expression of ADRB2. Two UDP-glucuronosyltransferases, UGT2B15 and UGT2B17, involved in phase II metabolism of androgens, were strongly downregulated in two LNCaP shADRB2 cell lines. The low-ADRB2 LNCaP cell lines displayed lowered glucuronidation activities towards androgens than high-ADRB2 cells. Furthermore, increased levels of testosterone and enhanced androgen responsiveness were observed in LNCaP cells expressing low level of ADRB2. Interestingly, these cells grew faster than high-ADRB2 LNCaP cells, and sustained their low glucuronidation activity in castrated NOD/SCID mice. ADRB2 immunohistochemical staining intensity correlated with UGT2B15 staining intensity in independent TMA studies and with UGT2B17 in one TMA study. Similar to ADRB2, we show that low levels of UGT2B15 are associated with a more rapid CRPC progression. We propose a novel mechanism by which ADRB2 may affect the development of CRPC through downregulation of UGT2B15 and UGT2B17.

• Rud, Erik; Baco, Eduard; Klotz, Dagmar; Rennesund, Kristin; Svindland, Aud & Berge, Viktor [Show all 13 contributors for this article] (2015). Does preoperative magnetic resonance imaging reduce the rate of positive surgical margins at radical prostatectomy in a randomised clinical trial? European Urology. ISSN 0302-2838. 68(3), p. 487–496. doi: 10.1016/j.eururo.2015.02.039. Full text in Research Archive
• Baco, Eduard; Rud, Per Erik; Vlatkovic, Ljiljana; Svindland, Aud; Eggesbø, Heidi Beate & Hung, Andrew J. [Show all 10 contributors for this article] (2015). Predictive value of magnetic resonance imaging determined tumor contact length for extracapsular extension of prostate cancer. Journal of Urology. ISSN 0022-5347. 193(2), p. 466–472. doi: 10.1016/j.juro.2014.08.084. Full text in Research Archive
• Bruun, Jarle; Kolberg, Matthias; Ahlquist, Terje Cruickshank; Røyrvik, Ellen Christine; Nome, Torfinn & Leithe, Edward [Show all 18 contributors for this article] (2015). Regulator of chromosome condensation 2 identifies high-risk patients within both major phenotypes of colorectal cancer. Clinical Cancer Research. ISSN 1078-0432. 21(16), p. 3759–3770. doi: 10.1158/1078-0432.CCR-14-3294. Full text in Research Archive
• Baco, Eduard; Ukimura, Osamu; Rud, Per Erik; Vlatkovic, Ljiljana; Svindland, Aud & Aron, Manju [Show all 13 contributors for this article] (2015). Magnetic Resonance Imaging-Transectal Ultrasound Image-fusion Biopsies Accurately Characterize the Index Tumor: Correlation with Step-sectioned Radical Prostatectomy Specimens in 135 Patients. European Urology. ISSN 0302-2838. 67(4), p. 787–794. doi: 10.1016/j.eururo.2014.08.077. Full text in Research Archive
• Rud, Per Erik; Klotz, Dagmar; Rennesund, Kristin; Baco, Eduard; Johansen, Truls Erik B & Diep, Lien My [Show all 9 contributors for this article] (2014). Preoperative magnetic resonance imaging for detecting uni- and bilateral extraprostatic disease in patients with prostate cancer. World Journal of Urology. ISSN 0724-4983. 33(7), p. 1015–1021. doi: 10.1007/s00345-014-1362-x. Full text in Research Archive
• Hveem, Tarjei Sveinsgjerd; Merok, Marianne Aarstad; Pretorius, Maria; Novelli, Marco; Silihagen, Mette & Sjo, Ole Helmer [Show all 12 contributors for this article] (2014). Prognostic impact of genomic instability in colorectal cancer. British Journal of Cancer. ISSN 0007-0920. 110(8), p. 2159–2164. doi: 10.1038/bjc.2014.133. Full text in Research Archive
• Rud, Per Erik; Klotz, Dagmar; Rennesund, Kristin; Baco, Eduard; Berge, Viktor & Diep, Lien My [Show all 11 contributors for this article] (2014). Detection of the index tumour and tumour volume in prostate cancer using T2-weighted and diffusion-weighted magnetic resonance imaging (MRI) alone. BJU International. ISSN 1464-4096. 114(6), p. E32–E42. doi: 10.1111/bju.12637. Full text in Research Archive
• Røe, Oluf Dimitri; Oppegaard, Per Arne; Revheim, Mona Elisabeth & Svindland, Aud (2014). Adrenocortical carcinoma mimicking lung cancer and responding to vinorelbine/carboplatin and pemetrexed/carboplatin. BMJ Case Reports. p. 1–7. doi: 10.1136/bcr-2014-206225. Full text in Research Archive Show summary

  Adrenocortical carcinoma is an aggressive cancer, with an incidence of 0.5–2 per million. We present a case of adrenocortical carcinoma with all the clinical and partly immunohistochemical features of disseminated undifferentiated lung cancer, and ‘accidentally’ treated as such. Four cycles of carboplatin–vinorelbine conferred partial response in the adrenal, lung and disappearance of a 2 cm subcutaneous iliac nodule that had appeared suddenly before the first course. Owing to progression, four cycles of carboplatin–pemetrexed were administered inducing partial response and then stable disease for an additional 12 months. As fluoro-D-glucose (FDG)-positron emission tomography (PET) only showed activity in the adrenal, laparoscopic adrenalectomy was performed. Three months later FDG-PET revealed a lung nodule unresponsive to carboplatin–pemetrexed, removed by wedge resection. Finally, re-evaluation by a tertiary centre confirmed adrenocortical carcinoma with Ki67—50% in the adrenal and the lung. The patient is alive and tumour free almost 3.5 years after retrospective diagnosis of metastatic adrenocortical cancer.

• Courivaud, Fredric A A; Kazaryan, Airazat M.; Lund, Alice; Orszagh, Vivian C; Svindland, Aud & Marangos, Irina Pavlik [Show all 11 contributors for this article] (2014). Thermal fixation of swine liver tissue after magnetic resonance-guided high-intensity focused ultrasound ablation. Ultrasound in Medicine and Biology. ISSN 0301-5629. 40(7), p. 1564–1577. doi: 10.1016/j.ultrasmedbio.2014.02.007. Full text in Research Archive
• Bruun, Jarle; Kolberg, Matthias; Nesland, Jahn M; Svindland, Aud; Nesbakken, Arild & Lothe, Ragnhild A (2014). Prognostic significance of β-catenin, E-cadherin, and SOX9 in colorectal cancer: Results from a large population-representative series. Frontiers in Oncology. 4 MAY. doi: 10.3389/fonc.2014.00118. Full text in Research Archive
• Baco, Eduard; Rud, Per Erik; Ukimura, Osamu; Vlatkovic, Ljiljana; Svindland, Aud & Matsugasumi, Toru [Show all 9 contributors for this article] (2014). Effect of targeted biopsy guided by elastic image fusion of MRI with 3D-TRUS on diagnosis of anterior prostate cancer. Urologic Oncology. ISSN 1078-1439. 32(8), p. 1300–1307. doi: 10.1016/j.urolonc.2014.07.014. Full text in Research Archive
• Steinsvik, Eivind Andreas Svaboe; Axcrona, Karol; Angelsen, Anders; Beisland, Christian; Dahl, Alv A & Eri, Lars Magne [Show all 9 contributors for this article] (2013). Does a surgeon’s annual radical prostatectomy volume predict the risk of positive surgical margins and urinary incontinence at one-year follow-up? Findings from a prospective national study. Scandinavian Journal of Urology and Nephrology. ISSN 0036-5599. 47(2), p. 92–100. doi: 10.3109/00365599.2012.707684. Full text in Research Archive
• Itkonen, Harri; Minner, S; Guldvik, Ingrid Jenny; Sandmann, M; Tsourkalis, Maria & Berge, Viktor [Show all 9 contributors for this article] (2013). O-GlcNAc Transferase Integrates Metabolic Pathways to Regulate the Stability of c-MYC in Human Prostate Cancer Cells. Cancer Research. ISSN 0008-5472. 73. doi: 10.1158/0008-5472.CAN-13-0549. Full text in Research Archive
• Merok, Marianne Aarstad; Ahlquist, Terje Cruickshank; Røyrvik, Ellen Christine; Tufteland, Kjersti Forberg; Hektoen, Merete & Sjo, Ole Helmer [Show all 10 contributors for this article] (2013). Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: results from a large, consecutive Norwegian series. Annals of Oncology. ISSN 0923-7534. 24(5), p. 1274–1282. doi: 10.1093/annonc/mds614. Full text in Research Archive
• Lazarevic, Bato; Hammarstrøm, Clara Louise; Yang, Jing; Ramberg, Håkon Andre; Diep, Lien My & Karlsen, Steinar [Show all 10 contributors for this article] (2012). The effects of short-term genistein intervention on prostate biomarker expression in patients with localised prostate cancer before radical prostatectomy. British Journal of Nutrition. ISSN 0007-1145. 108(12), p. 2138–2147. doi: 10.1017/S0007114512000384. Full text in Research Archive
• Sjo, Ole Helmer; Merok, Marianne Aarstad; Svindland, Aud & Nesbakken, Arild (2012). Prognostic Impact of Lymph Node Harvest and Lymph Node Ratio in Patients With Colon Cancer. Diseases of the Colon & Rectum. ISSN 0012-3706. 55(3), p. 307–315. doi: 10.1097/DCR.0b013e3182423f62. Full text in Research Archive
• Berge, Viktor; Berg, Rolf Eigil; Hoff, Jon Roar; Wessel, Nicolai; Svindland, Aud & Karlsen, Steinar [Show all 7 contributors for this article] (2012). Five-year progression-free survival in 577 patients operated on with laparoscopic radical prostatectomy for localized prostate cancer. Scandinavian Journal of Urology and Nephrology. ISSN 0036-5599. 46(1), p. 8–13. doi: 10.3109/00365599.2011.604790. Full text in Research Archive
• Sirnes, Solveig; Bruun, Jarle; Kolberg, Matthias; Kjenseth, Ane Hansen; Lind, Guro Elisabeth & Svindland, Aud [Show all 11 contributors for this article] (2012). Connexin43 acts as a colorectal cancer tumor suppressor and predicts disease outcome. International Journal of Cancer. ISSN 0020-7136. 131(3), p. 570–581. doi: 10.1002/ijc.26392. Full text in Research Archive
• Sjo, Ole Helmer; Berg, Marianne; Merok, Marianne Aarstad; Kolberg, Matthias; Svindland, Aud & Lothe, Ragnhild A [Show all 7 contributors for this article] (2011). Peritoneal Carcinomatosis of Colon Cancer Origin: Highest Incidence in Women and in Patients With Right-Sided Tumors. Journal of Surgical Oncology. ISSN 0022-4790. 104(7), p. 792–797. doi: 10.1002/jso.21959. Full text in Research Archive
• Lund, Terje; Svindland, Aud; Pepaj, Milaim; Jensen, Aase-Brith Ellefsen; Berg, Jens Petter & Kilhovd, Bente [Show all 7 contributors for this article] (2011). Fibrin(ogen) may be an important target for methylglyoxal-derived AGE modification in elastic arteries of humans. Diabetes & vascular disease research. ISSN 1479-1641. 8(4), p. 284–294. doi: 10.1177/1479164111416831. Full text in Research Archive
• Ramberg, Håkon Andre; Alshbib, Ayham; Berge, Viktor; Svindland, Aud & Tasken, Kristin Austlid (2011). Regulation of PBX3 expression by androgen and Let-7d in prostate cancer. Molecular Cancer. 10. doi: 10.1186/1476-4598-10-50. Full text in Research Archive Show summary

  Background The pre-leukemia transcription factor 3 (PBX) is part of the PBX family of transcription factors, which is known to regulate genes involved in differentiation of urogenital organs and steroidogenesis. This is of interest with regard to prostate cancer progression as regulation of steroidogenesis is one of the mechanisms involved in the development of castration-resistant prostate cancer. In light of this we wanted to investigate the possible involvement of androgen regulation of PBX3 expression in prostate cancer. Results In this study, we show that PBX3 is post-transcriptionally regulated by androgen in prostate cancer cells and that the effect might be independent of the androgen receptor. Furthermore, PBX3 was identified as a target of Let-7d, an androgen regulated microRNA. Let-7d was down-regulated in malignant compared to benign prostate tissue, whereas up-regulation of PBX3 expression was observed. Conclusions We demonstrate that PBX3 is up-regulated in prostate cancer and post- transcriptionally regulated by androgen through Let-7d.

• Færden, Arne Engebret; Sjo, Ole Helmer; Bukholm, Ida Rashida Khan; Andersen, Solveig Norheim; Svindland, Aud & Nesbakken, Arild [Show all 7 contributors for this article] (2011). Lymph Node Micrometastases and Isolated Tumor Cells Influence Survival in Stage I and II Colon Cancer. Diseases of the Colon & Rectum. ISSN 0012-3706. 54(2), p. 200–206. doi: 10.1007/DCR.0b013e3181fd4c7c. Full text in Research Archive
• Lazarevic, Bato; Boezelijn, Gro; Diep, Lien My; Kvernrød, Kristin; Øgren, Hans Olov & Ramberg, Håkon Andre [Show all 16 contributors for this article] (2011). Efficacy and Safety of Short-Term Genistein Intervention in Patients with Localized Prostate Cancer Prior to Radical Prostatectomy: A Randomized, Placebo-Controlled, Double-Blind Phase 2 Clinical Trial. Nutrition and Cancer. ISSN 0163-5581. 63(6), p. 889–898. doi: 10.1080/01635581.2011.582221. Full text in Research Archive
• Nesbakken, Arild; Kristinsson, Jon Adalsteinn; Svindland, Aud & Lunde, Ole Christian (2011). ENDOSCOPIC SNARE RESECTION FOLLOWED BY LASER ABLATION IN THE TREATMENT OF LARGE, SESSILE RECTAL ADENOMAS. Scandinavian Journal of Surgery. ISSN 1457-4969. 100(2), p. 99–104. Full text in Research Archive
• Kvåle, Rune; Møller, Bjørn; Wahlqvist, Rolf; Fosså, Sophie Dorothea; Berner, Aasmund & Busch, Christer [Show all 10 contributors for this article] (2009). Concordance between Gleason scores of needle biopsies and radical prostatectomy specimens: a population-based study. BJU International. ISSN 1464-4096. 103(12), p. 1647–1654. doi: 10.1111/j.1464-410X.2008.08255.x. Full text in Research Archive
• Færden, Arne Engebreyh; Sjo, Ole Helmer; Andersen, Solveig Norheim; Hauglann, Beate; Naimy, Nazir & Gravedaug, B [Show all 10 contributors for this article] (2008). Sentinel Node Mapping does not Improve Staging of Lymph Node Metastasis in Colonic Cancer. Diseases of the Colon & Rectum. ISSN 0012-3706. 51(6), p. 891–896. doi: 10.1007/s10350-007-9185-0. Full text in Research Archive
• Seierstad, SL; Svindland, Aud; Larsen, S; Rosenlund, G; Torstensen, BE & Evensen, O (2008). Development of intimal thickening of coronary arteries over the lifetime of Atlantic salmon, Salmo salar L., fed different lipid sources. Journal of Fish Diseases. ISSN 0140-7775. 31, p. 401–413. doi: 10.1111/j.1365-2761.2008.00913.x. Full text in Research Archive
• Seierstad, Sverre; Svindland, Aud; Larsen, Stig; Rosenlund, G; Evensen, Øystein & Torstensen, Bente (2008). Development of intimal thickening of coronary arteries over the lifetime of Atlantic salmon, Salmo salar L., fed different lipid sources. Journal of Fish Diseases. ISSN 0140-7775. 31, p. 401–413. Full text in Research Archive
• Kvissel, Anne Katrine; Ramberg, Håkon; Eide, Turid; Svindland, Aud; Skålhegg, Bjørn Steen & Tasken, Kristin Austlid (2007). Androgen dependent regulation of protein kinase A subunits in prostate cancer cells. Cellular Signalling. ISSN 0898-6568. 19(2), p. 401–409. doi: 10.1016/j.cellsig.2006.07.011. Full text in Research Archive
• Seierstad, S.L.; Poppe, T.T.; Koppang, E.O.; Svindland, Aud; Rosenlund, G. & Frøyland, L. [Show all 7 contributors for this article] (2005). Influence of dietary lipid composition on cardiac pathology in farmed Atlantic salmon, Salmo salar L. Journal of Fish Diseases. ISSN 0140-7775. 28(11), p. 677–90. Full text in Research Archive
• Korkmaz, Ceren; Korkmaz, Kemal; Kurys, Piotr Jerzy; Elbi, Cem; Ling, Wang & Klokk, Tove Irene [Show all 11 contributors for this article] (2005). Molecular cloning and characterization of STAMP2, an andogen-regulated six transmembrane protein that is overexpressed in prostate cancer. Oncogene. ISSN 0950-9232. 24(31), p. 4934–45. Full text in Research Archive
• Eliassen, Knut A.; Brodal, Bjørn P; Svindland, Aud; Osmundsen, Harald; Rønning, H. & Djurovic, Srdjan [Show all 7 contributors for this article] (2005). Activity of peroxisomal enzymes, and levels of polyamines in LPA-transgenic mice on two different diets. Lipids in Health and Disease. 4(23). Full text in Research Archive
• Tasken, Kristin Austlid; Angelsen, A.; Svindland, Aud; Eide, Turid; Berge, V. & Wahlquist, R. [Show all 7 contributors for this article] (2005). Markører for påvisning av prostatakreft og prediksjon av prognose. Tidsskrift for Den norske legeforening (Tidsskriftet). ISSN 0029-2001. 125(23), p. 3279–82. Full text in Research Archive
• Eliassen, Knut; Brodal, B.P.; Svindland, Aud; Osmundsen, Harald; Rønning, H.F. & Djurovic, Srjdan [Show all 7 contributors for this article] (2005). Activity of peroxisomal enzymes, and levels of polyamines in LPA-transgenic mice on two different diets. Lipids in Health and Disease. 4, p. 23–23. Full text in Research Archive
• Seierstad, Sverre; Poppe, Trygve; Koppang, Erling Olaf; Svindland, Aud; Rosenlund, Grethe & Frøyland, Livar [Show all 7 contributors for this article] (2005). Influence of dietary lipid composition on cardiac pathology in farmed Atlantic salmon, Salmo salar L. Journal of Fish Diseases. ISSN 0140-7775. 28(11), p. 677–690. Full text in Research Archive
• Teivainen, P.A.; Eliassen, Knut; Berg, Kåre; Torsdalen, Kari & Svindland, Aud (2004). Atherogenesis and vascular calcification in mice expressing the human LPA gene. Pathophysiology. ISSN 0928-4680. 11, p. 113–120. Full text in Research Archive
• Storås, Tryggve; Gjesdal, Kjell-Inge; Svindland, Aud; Viktil, Ellen & Geitung, John Terje (2004). Dynamic First Pass 3D EPI of the Prostate: Accuracy in Tumor Location. Acta Radiologica. ISSN 0284-1851. 45, p. 584–590. Full text in Research Archive
• Teivainen, Paivi; Eliassen, Knut A.; Berg, Kåre; Torsdalen, K. & Svindland, Aud (2004). Atherogenesis and vascular calicification in mice expressing the human LPA gene. Pathophysiology. ISSN 0928-4680. 11, p. 113–120. Full text in Research Archive
• Ilebekk, Arnfinn & Svindland, Aud (2003). Distrubution of neuropeptide Y Y1 and Y2 receptors in the postmortem human heart. Peptides. ISSN 0196-9781. 24, p. 255–262. Full text in Research Archive
• Berg, Kåre; Svindland, Aud; Smith, Adrian John; Lawn, Richard M; Djurovic, Srjdan & Aleström, Annette [Show all 8 contributors for this article] (2002). Spontaneous atherosclerosis in the proximal aorta of LPA transgenic mice on a normal diet. Atherosclerosis. ISSN 0021-9150. 163(1), p. 99–104. Full text in Research Archive
• Berg, K. Andersen; Svindland, Aud; Smith, A.J.; Lawn, R. M.; Djorovic, S. & Alestrøm, Peter [Show all 7 contributors for this article] (2002). Spontaneous atherosclerosis in the proximal aorta of LPA transgenic mice on a normal diet. Atherosclerosis. ISSN 0021-9150. 163(1), p. 99–104. Full text in Research Archive
• Sætre, Torunn; Høiby, Ernst Arne; Aspelin, Trude; Lermark, Gro; Egeland, Thore & Svindland, Aud [Show all 7 contributors for this article] (2001). Aminoethyl-isothiourea inhibits the increase in plasma endothelin-1 caused by serogroup A streptococci and prolongs survival in rat peritoneal sepsis. Shock. ISSN 1073-2322. 15(6), p. 453–454. Full text in Research Archive
• Smith, Adrian John; Svindland, Aud; Berg, Kåre; Lawn, Richard M; Djurovic, Srjdan & Aleström, Peter [Show all 8 contributors for this article] (2000). Histopathology of arterial lesions in LPA transgenic mice on cholesterol-enriched chow. Atherosclerosis. ISSN 0021-9150. 153, p. 349–354. Full text in Research Archive
• Eri, Lars Magne & Svindland, Aud (2000). Can prostate epithelial content predict response to hormonal treatment of patients with benign prostatic hyperplasia? Urology. ISSN 0090-4295. 56(1), p. 261–265. Full text in Research Archive
• Svindland, Aud; Berg, Kåre; Eliassen, K.; Lawn, R. M.; Djurovic, Srdjan & Alestrøm, Peter [Show all 8 contributors for this article] (2000). Histopathology of arterial lesions in LPA transgenic mice on cholesterol-enriched chow. Atherosclerosis. ISSN 0021-9150. 153(2), p. 349–354. Full text in Research Archive
• Kanellopoulos, G.K.; Svindland, Aud; Goverud, I.; Ilebekk, Arnfinn & Kvernebo, Knut (1999). Transventricular non-transmural laser treatment of hypoperfused porcine myocardium acutely reduces left ventricular contractile function. European Journal of Cardio-Thoracic Surgery. ISSN 1010-7940. 16, p. 135–143. Full text in Research Archive Show summary

  Keyword: Hjerte.

• Hvaal, Kjetil; Mathisen, S.R.; Svindland, Aud; Nordsletten, Lars & Skjeldal, Sigmund (1999). Protective effect of the endothelin antagonist Bosentan against ischemic skeletal muscle necrosis. Acta Orthopaedica Scandinavica. ISSN 0001-6470. p. 293–297. Full text in Research Archive
• Hvaal, Kjetil; Mathisen, S.R.; Svindland, Aud; Nordsletten, Lars & Skjeldal, Sigmund (1999). Protective effect of the endothelin antagonist Bosentan against ischemic skeletal muscle necrosis. Acta Orthopaedica Scandinavica. ISSN 0001-6470. 70, p. 293–297. Full text in Research Archive
• Hvaal, Kjetil; Mathisen, S.R.; Svindland, Aud; Nordsletten, Lars & Skjeldal, Sigmund (1999). Carvedilol reduces ischaemic skeletal muscle necrosis. Journal of Orthopaedic Research. ISSN 0736-0266. 17, p. 720–724. Full text in Research Archive
• Hvaal, Kjetil; Mathisen, S.R.; Svindland, Aud; Nordsletten, Lars & Skjeldal, Sigmund (1999). Effect of the Endothelin antagonist Bosentan on ischaemic skeletal muscle necrosis. Acta Orthopaedica Scandinavica. ISSN 0001-6470. 70(3), p. 293–297. Full text in Research Archive
• Svindland, Aud; Eri, Lars Magne & Tveter, Kjell (1996). Morphometry of benign prostatic hyperplasia during androgen suppressive therapy. Scandinavian Journal of Urology and Nephrology. ISSN 0036-5599. 30(179), p. 113–117. Full text in Research Archive
• Hvaal, Kjetil; Svindland, Aud; Nordsletten, Lars & Skjeldal, Sigmund (1996). No increasing injury during early reperfusion of skeletal muscle. Scandinavian Journal of Clinical and Laboratory Investigation. ISSN 0036-5513. 56, p. 11–16. Full text in Research Archive
• Carlsen, Karin C. Lødrup; Svindland, Aud; Refvem, Olav Kaare & Carlsen, Kai-Håkon (1992). Plutselig uventet doed og nesten doed hos barn med astma. Tidsskrift for Den norske legeforening (Tidsskriftet). ISSN 0029-2001. 112, p. 620–622. Full text in Research Archive

View all works in NVA

• Braadland, PR; Giskeødegård, Guro F.; Sandsmark, Elise; Bertilsson, Helena; Wood, Leslie Euceda & Hansen, Ailin Falkmo [Show all 15 contributors for this article] (2016). Distinguishing indolent from agressive prostate cancer by ex vivo metabolic fingerprinting. Full text in Research Archive
• Baco, Eduard; Rud, Erik; Svindland, Aud & Eggesbø, Heidi Beate (2013). Anterior prostate cancer: gleason score based on MRI/TRUS elastic image fusion guided prostate biopsy vs prostatectomy. Scandinavian Journal of Urology and Nephrology. ISSN 0036-5599. 47, p. 15–15. Full text in Research Archive
• Færden, Arne E; Sjo, Ole Helmer; Andersen, Solveig Norheim; Hauglann, Berit; Naimy, Nazir & Gravdehaug, Berit [Show all 10 contributors for this article] (2007). Sentinel node mapping does not improve staging of lymph node metastases in colonic cancer. Full text in Research Archive
• Færden, Arne E; Sjo, Ole Helmer; Andersen, Solveig Norheim; Hauglann, Berit; Naimy, Nazir & Gravdehaug, Berit [Show all 10 contributors for this article] (2007). Sentinel node diagnostikk forbedrer ikke diagnostikk av lymfeknutemetastaser ved colon cancer. Full text in Research Archive
• Eliassen, Knut; Teivainen-Lædre, Päivi A.; Svindland, Aud; Nissen-Meyer, L.S.; Crooke, R.M. & Graham, M.J. [Show all 7 contributors for this article] (2006). Significant reduction of lipoprotein (A) level in LPA-transgenic mice after treatment with an antisense inhibitor of the LPA gene. Atherosclerosis Supplements. ISSN 1567-5688. p. 532–532. Full text in Research Archive
• Nesbakken, Arild; Lunde, Ole Christian; Krisstinson, J. & Svindland, Aud (2002). Premaligne rectum polypper behandlet med slyngereseksjon og laser behandling. Full text in Research Archive
• Flørenes, Tor; Bay, Dag; Gjertsen, Ø. & Svindland, Aud (2002). Subintimal kanalens utseende etter lang tids åpenhet. Full text in Research Archive
• Svindland, Aud (2002). Undersøkelse av preparater etter prostatectomi. Full text in Research Archive
• Svindland, Aud (2002). Klassifikasjon av blære tumores. Full text in Research Archive
• Svindland, Aud (2002). Histologisk undersøkelse av prostata biopsier. Full text in Research Archive

View all works in NVA